The longevity tetrapeptide studied for resetting the cellular clock
Injection · 503A Compounding
Educational content. This page describes Epithalon for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Researched and maintained by the PepHookup team. Regulatory status last verified April 12, 2026.
Epithalon (also spelled Epitalon, and listed by the FDA as Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), just four amino acids. It was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology and was designed to reproduce the active fragment of Epithalamin, a bovine pineal gland extract studied in Soviet and Russian gerontology since the 1980s.
It belongs to a class Khavinson called peptide bioregulators, very short peptides proposed to fine-tune gene expression in specific tissues. Epithalon is the most studied of these for longevity, with a literature spanning cell cultures, fruit flies, rodents, primates, and a handful of human cohorts. Much of that body of work originates from a single research lineage, a caveat that matters when weighing the evidence.
The headline mechanism is telomerase activation. In cultured human cells, Epithalon induces expression of the telomerase catalytic subunit (hTERT), restores enzyme activity, and elongates telomeres, allowing fibroblasts to divide roughly ten passages past their normal Hayflick limit. A 2025 study from a UK university reproduced dose-dependent telomere extension through hTERT and telomerase upregulation in normal human cells, the first prominent confirmation outside the originating group.
Epithalon also behaves as an epigenetic regulator rather than a classic receptor ligand. As a small peptide it can reach the cell nucleus, bind specific DNA sequences and histones, and shift transcription of genes tied to neurogenesis, circadian rhythm, and cellular maintenance. This sequence-level interaction is the proposed basis for its tissue-targeted effects.
A third axis is the pineal gland. In aged rhesus monkeys Epithalon stimulated evening melatonin and helped normalize circadian cortisol. The related human studies mostly used the pineal extract Epithalamin or a sublingual form, so the pineal and sleep benefits are better supported for those preparations than for injectable Epithalon itself. The peptide also lowers oxidative stress, an effect seen across fruit fly, oocyte, and rodent models.
The longevity tetrapeptide studied for resetting the cellular clock
Epithalon is thought to work on three fronts. It induces hTERT and reactivates telomerase to elongate telomeres in human cells, it acts as a short-peptide epigenetic regulator that binds DNA and histones to shift expression of clock, neurogenesis, and maintenance genes, and it supports pineal melatonin output while reducing oxidative stress. The telomerase effect now has independent in-vitro confirmation, while the pineal and longevity benefits rest largely on animal models and the related extract Epithalamin.
Epithalon induced hTERT expression and telomerase activity and elongated telomeres in telomerase-negative somatic cells, enabling them to surpass the Hayflick limit by roughly ten additional divisions.
Khavinson VKh, Bondarev IE, Butyugov AA · Bull Exp Biol Med, 135(6):590-592 (2003) · PubMed
Reproduced dose-dependent telomere extension in normal cells through hTERT mRNA and telomerase upregulation. In cancer cells, lengthening occurred via Alternative Lengthening of Telomeres (ALT), a finding relevant to cancer-safety questions.
Al-Dulaimi S, Thomas R, Matta S, Roberts T · Biogerontology, 26(5):178 (2025) · PubMed
Six courses of the pineal preparation Epithalamin over three years lowered functional age and improved exercise tolerance. At 12 years overall mortality was about 28% lower and cardiovascular mortality roughly twofold lower versus controls on the same baseline therapy.
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA · Bull Exp Biol Med, 142(3):356-359 (2006) · PubMed
Parabulbar Epitalon (5 mcg per eye for 10 days) was associated with improved retinal function and broadened visual fields in a majority of patients, with no reported adverse effects. The study was uncontrolled and conducted at the originating institute.
Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A · Neuro Endocrinol Lett, 23(4):365-368 (2002) · PubMed
start low, go slow
Subcutaneous Injection
Subcutaneous Injection: Cyclical pattern mirroring published research. Most protocols specify a total cycle dose rather than a fixed daily dose.
Any dosing is determined by a licensed provider. The figures here reflect published research patterns, not an FDA-approved regimen.
Epithalon is used in short pulsed cycles (10-20 days on, then months off) rather than continuously, consistent with how the geroprotection studies were structured.
Because the peptide supports endogenous melatonin, some practitioners favor evening administration and advise against layering in supplemental melatonin during an active cycle.
Animal safety has been favorable. Lifetime dosing in mice produced no adverse effects and did not raise tumor incidence, and in those models it was associated with fewer tumors.
Human safety data are limited and come mostly from small, often uncontrolled studies by the originating group, where no adverse effects were reported. A 2025 review concluded that formal short- and long-term toxicity studies are still needed before Epithalon could be considered an approved active ingredient.
The FDA, in placing Epitalon in its restricted compounding category, cited immunogenicity concerns and limited human clinical data. No large randomized controlled trials and no FDA approval exist for any indication.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| Epithalon | Anti-Aging & Longevity | Injection | 10-20 days, every 4-6 months | A four-amino-acid peptide whose telomerase activation in human cells has now been independently replicated, though most longevity claims still rest on animal data |
| SS-31 (Elamipretide) | Mitochondrial restoration and rare mitochondrial disease | Subcutaneous injection (daily); IV in trials | Ongoing daily dosing | The first FDA-approved mitochondria-targeted therapeutic; binds cardiolipin on the inner mitochondrial membrane to support electron transport efficiency |
| GHK-Cu | Anti-Aging & Skin Regeneration | Topical, Injection | 8-12 weeks | A naturally occurring copper-carrier peptide that rebuilds the skin matrix and, per gene-expression analysis, shifts expression of about a third of human genes toward repair |
| Sermorelin | GH restoration and healthy aging | Subcutaneous injection, daily at bedtime | 3-6 months | The GHRH analog with prior FDA approval and a multi-decade clinical record, preserving natural feedback rather than replacing growth hormone |
| Glutathione | Antioxidant & Detoxification | IV, Oral, Sublingual, Topical | Ongoing supplementation | The body's own master antioxidant, with controlled human data showing oral and sublingual forms can raise body stores and immune markers |
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.
Listed in Category 2 as Epitalon. FDA cited immunogenicity risks and limited clinical trial data in humans. Not eligible for compounding under the interim policy.
Listed as 'Epitalon' in 503A Category 2
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A “Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa.” Neuro Endocrinol Lett, 23(4):365-368 (2002)
Ivko OM, Linkova NS, Ilina AR, Sharova AA, Ryzhak GA “AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging.” Adv Gerontol, 33(3):429-435 (2020)
Looking into Epithalon? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA mitochondria-targeted tetrapeptide that stabilizes cardiolipin to support cellular energy.
FDA-approved as Forzinity for Barth syndrome in 2025; the first mitochondria-targeted therapeutic approved.
A tripeptide-copper complex that supports skin regeneration and wound healing.
Naturally occurring in plasma; levels decline with age. Widely used in topical and compounded formulations.
A 29-residue GHRH analog that prompts the pituitary to release endogenous growth hormone.
Formerly marketed as Geref for pediatric GH deficiency; discontinued in 2008 for commercial reasons.
“Advanced peptide therapies and personalized luxury care for optimal health, vitality, and longevity.”
Vetted providers offering Epithalon.